Upper urinary-tract urothelial carcinomas (UTUC) constitute 5% of urothelial malignancies. Prognostic biomarkers would allow lower risk surgical approaches for less aggressive UTUCs. One biomarker—Ki-67/mindbomb E3 ubiquitin protein ligase 1 (Ki-67/MIB-1)—shows promise in UTUC, but there have been conflicting findings regarding its prognostic role. The systematic review and meta-analysis aim to determine the prognostic value of Ki-67/MIB-1 in UTUC in terms of UTUC-specific mortality rate, 5-year disease-free survival, and 5-year overall survival (including disease-specific survival).
Methods:
A systematic review of the current literature produced 654 records. A total of 13 studies consisting of 1030 patients were finally included in the meta-analysis. Hazard ratios (HRs) with 95% confidence intervals (CI) were extracted or estimated. The individual HR estimates were combined into a pooled HR using a fixed-effects model that summed homogeneity of the individual true HRs.
Results:
Patients with Ki-67/MIB-1 overexpression displayed significantly higher UTUC-specific mortality rate (pooled HR: 2.14, 95% CI: 1.73–2.64; p<0.00001), significantly reduced 5-year disease-free survival (pooled HR: 2.27, 95% CI: 1.79–2.92; p<0.00001), and significantly reduced 5-year overall survival (pooled HR=1.77; 95% CI: 1.39–2.23 p<0.00001). There was significant heterogeneity detected in the UTUC-specific mortality rate meta-analysis (I2=63%) and the 5-year disease-free survival meta-analysis (I2=65%), but there was no significant heterogeneity detected in the 5-year overall survival meta-analysis (I2=0%). Egger's testing showed that none of the outcomes were influenced by publication bias (p>0.05).
Conclusions:
Ki-67/MIB-1 overexpression shows promise as a prognostic biomarker for UTUC patients and requires further investigation.
Get full access to this article
View all access options for this article.
References
1.
ZigeunerR, PummerK. Urothelial carcinoma of the upper urinary tract: Surgical approach and prognostic factors. Eur Urol, 2008; 53:720–731.
2.
MunozJJ, EllisonLM. Upper tract urothelial neoplasms: Incidence and survival during the last 2 decades. J Urol, 2000; 164:1523–1525.
3.
BrownGA, BusbyJE, WoodCG, et al.Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int, 2006; 98:1176–1180.
4.
ChromeckiTF, BensalahK, RemziM, et al.Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol, 2011; 8:440–447.
5.
LughezzaniG, BurgerM, MargulisV, et al.Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur Urol, 2012; 62:100–114.
6.
EltzS, ComperatE, CussenotO, RouprêtM. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int, 2008; 102:532–535.
7.
MorenoSJ, FernándezPC, MazuecosLM, et al.[Systematic review about the usefulness and prognostic value of the p53 oncoprotein and proliferation marker Ki-67 for upper urinary tract transitional cell carcinoma]. Arch Esp Urol, 2004; 57:327–335.
8.
EggerM, SmithGD, PhillipsAN. Meta-analysis: Principles and procedures. BMJ, 1997; 315:1533.
9.
KuJH, ByunS-S, JeongH, KwakC, KimHH, LeeSE. The role of p53 on survival of upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Clin Genitourin Cancer, 2013; 11:221–228.
10.
SimonR, AltmanDG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer, 1994; 69:979.
11.
ChowdhuryGM, KojimaK, KanayamaHo, TsujiM, KurokawaY, KagawaS. The proliferation index of MIB–1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer, 1996; 78:827–833.
12.
KillIR. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci, 1996; 109:1253–1263.
13.
MasudaM, IkiM, TakanoY, et al.Prognostic significance of Ki-67 labeling index in urothelial tumors of the renal pelvis and ureter. J Urol, 1996; 155:1877–1881.
14.
KamaiT, TakagiK, AsamiH, ItoY, AraiK, YoshidaKI. Prognostic significance of p27Kip1 and Ki‐67 expression in carcinoma of the renal pelvis and ureter. BJU Int, 2000; 86:14–19.
15.
van RhijnBW, VisAN, van der KwastTH, et al.Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol, 2003; 21:1912–1921.
16.
FromontG, RouprêtM, AmiraN, et al.Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol, 2005; 48:764–770.
17.
KamijimaS, TobeT, SuyamaT, et al.The prognostic value of p53, Ki‐67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol, 2005; 12:941–947.
18.
CHENM, XU, Dan-feng, CUI, Xin-gang, GAO, Yi, Ji-zhongREN. Multivariate analysis of prognosis of patients with upper urinary tract transitional cell carcinoma. Acad J Second Mil Med Univ, 2008; 29:1217–1220. Chinese.
19.
JoungJY, YangSO, JeongIG, et al.Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int, 2008; 81:306–311.
20.
TsujimotoY, KomoriK, TsujimotoM, et al.[Immunohistochemical studies of p53, Ki-67, E-cadherin and beta-catenin on renal pelvic and ureteral cancers]. Nihon Hinyokika Gakkai Zasshi, 2008; 99:1–6.
21.
JeonHG, JeongIG, BaeJ, et al.Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology, 2010; 76:513. e7–e12.
22.
LyleSR, HsiehC-C, FernandezCA, ShuberAP. Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis. Res Rep Urol, 2012; 4:65.
23.
García-TelloA, AnguloJ, AndrésG, RamóndFF, Sánchez-ChapadoM, LópezJ. Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis. Actas Urol Esp, 2014; 38:506–514.
24.
GerdesJ, LiL, SchlueterC, et al.Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 1991; 138:867.
25.
UrruticoecheaA, SmithIE, DowsettM. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol, 2005; 23:7212–7220.
26.
van DierendonckJH, KeijzerR, van de VeldeCJ, CornelisseCJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Cancer Res, 1989; 49:2999–3006.
27.
HeidebrechtH, BuckF, HaasK, WackerH, ParwareschR. Monoclonal antibodies Ki‐S3 and Ki‐S5 yield new data on the ‘Ki-67’ proteins. Cell Prolif, 1996; 29:413–425.
28.
StarborgM, GellK, BrundellE, HoogC. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci, 1996; 109:143–153.
29.
NakopoulouL, VourlakouC, ZervasA, TzonouA, GakiopoulouH, DimopoulosM-A. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol, 1998; 29:146–154.
30.
Rioux-LeclercqN, TurlinB, BansardJ-Y, et al.Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology, 2000; 55:501–505.
31.
de AzambujaE, CardosoF, de CastroG, et al.Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patients. Br J Cancer, 2007; 96:1504–1513.
32.
LiR, HeydonK, HammondME, et al.Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy an analysis of patients in radiation therapy oncology group protocol 86–10. Clin Cancer Res, 2004; 10:4118–4124.
33.
HoDM-T, HsuC-Y, ChiangH. MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol, 2000; 76:97–102.
34.
LundinJ, NordlingS, Von BoguslawskyK, RobertsPJ, HaglundC. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res, 1994; 15:2659–2668.
35.
MartinB, PaesmansM, MascauxC, et al.Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-analysis. Br J Cancer, 2004; 91:2018–2025.
36.
SilvaSD, AgostiniM, NishimotoIN, et al.Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol, 2004; 40:688–696.
37.
HoosA, StojadinovicA, MastoridesS, et al.High Ki‐67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer, 2001; 92:869–874.
38.
LopezF, BellocF, LacombeF, et al.Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry, 1991; 12:42–49.
39.
BraunN, PapadopoulosT, Müller-HermelinkHK. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B, 1988; 56:25–33.
40.
SpyratosF, Ferrero-PoüsM, TrassardM, et al.Correlation between MIB-1 and other proliferation markers. Cancer, 2002; 94:2151–2159.
